<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03363893</url>
  </required_header>
  <id_info>
    <org_study_id>CT7001_001</org_study_id>
    <secondary_id>2017-002026-20</secondary_id>
    <nct_id>NCT03363893</nct_id>
  </id_info>
  <brief_title>Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies</brief_title>
  <official_title>A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carrick Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carrick Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in&#xD;
      advanced solid malignancies and to further investigate CT7001 as monotherapy or in&#xD;
      combination with standard therapy in specific participant groups with Triple Negative Breast&#xD;
      Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant&#xD;
      for patients with hormone receptor-positive (HR+ve) / human epidermal growth factor-2&#xD;
      negative (HER2-ve) breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Module 1 comprises two sequential parts:&#xD;
&#xD;
        -  Part A: First-in-human (FiH) dose escalation investigating the safety and tolerability&#xD;
           of CT7001 to identify the minimum biologically active dose (MBAD) and maximum tolerated&#xD;
           dose (MTD). Part A also includes a cohort expansion for breast cancer participants only:&#xD;
           this includes sequential tumour biopsies for evaluation of pharmacokinetic (PK),&#xD;
           pharmacodynamic (PD) and tumour responses. Recruitment is completed.&#xD;
&#xD;
        -  Part B: To refine the safety, tolerability, and PK and PD profiles of CT7001 monotherapy&#xD;
           in participants with advanced solid malignancies from up to four tumour- specific&#xD;
           cohorts, which may include, but is not limited to, triple-negative breast cancer,&#xD;
           ovarian cancer, small-cell lung cancer and prostate cancer.&#xD;
&#xD;
             -  Part B, Cohort 1, Triple-Negative Breast Cancer (M1B-1 TNBC) treated with CT7001 as&#xD;
                monotherapy. The module is completed.&#xD;
&#xD;
             -  Part B, Cohort 2, Prostate Cancer (M1B-2 CRPC) treated with CT7001 as monotherapy.&#xD;
                The module is completed.&#xD;
&#xD;
             -  Additional Module 1B Cohorts of up to 25 participants each may be added in the&#xD;
                future.&#xD;
&#xD;
        -  Module 4 is a study investigating the effect of food on the PK of CT7001 monotherapy in&#xD;
           participants with advanced solid malignancies. Recruitment is completed.&#xD;
&#xD;
        -  Module 2 is a Phase Ib/II, 3-part safety and efficacy study in participants with&#xD;
           hormone-receptor positive (HR+ve) and human epidermal growth factor-2 negative (HER2-ve)&#xD;
           breast cancer. This module will dose CT7001 in combination with fulvestrant. Module 2&#xD;
           consists of 3 parts - Part A, Part B and Part C. Module 2 Part A recruitment is&#xD;
           completed.Part B is double-blind, randomized and placebo-controlled Part C will be a&#xD;
           crossover from Part B. Module 2B/C is planned to open in 2021.&#xD;
&#xD;
        -  Module 6 is a Phase 1 study to explore the tolerability of, and the total and peak&#xD;
           exposure of, an enteric capsule formulation of CT7001 [CT7001(EC)], when given as&#xD;
           monotherapy to patients with advanced solid malignancies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 14, 2017</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Modular design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-Emergent Adverse Events and Laboratory Abnormalities (Safety and Tolerability)</measure>
    <time_frame>Screening to end of study</time_frame>
    <description>Type, incidence and severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration of CT7001 (and Fulvestrant, where applicable) (Cmax)</measure>
    <time_frame>After the first dose and during the dosing period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>After the first dose and during the dosing period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological Activity Parameters (Biomarkers) in Peripheral Blood</measure>
    <time_frame>Screening to end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumour Activity according to RECIST v1.1</measure>
    <time_frame>Baseline until disease progression or withdrawal from the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Baseline until disease progression or withdrawal from the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Baseline until disease progression or withdrawal from the study</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Advanced Solid Malignancies</condition>
  <arm_group>
    <arm_group_label>Module 1 Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced solid tumours receive CT7001 (samuraciclib) as oral monotherapy, in ascending dose cohorts, to identify the maximum tolerated dose (MTD), minimally biologically active dose (MBAD) and recommended dose for Phase II testing (RP2D). This module includes a cohort expansion of participants with breast cancer who provide paired biopsy samples.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 1 Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced solid tumours that may include, but is not limited to, triple negative breast cancer (TNBC), castrate-resistant prostate cancer (CRPC), small cell lung cancer (SCLC) or ovarian cancer, will receive CT7001 (samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.&#xD;
To date Module 1 Part B Arm has recruited a cohort of CRPC participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 1 Part B-1 TNBC Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with locally advanced or metastatic triple-negative breast cancer (TNBC) will receive CT7001(samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 2 Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer will receive CT7001 (samuraciclib) oral monotherapy in combination with fulvestrant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 2 Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer will be randomized to receive CT7001 (samuraciclib) or matching placebo as oral monotherapy at the dose determined in Module 2 Part A, in combination with fulvestrant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 2 Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer who were enrolled to the placebo arm in Module 2 Part B will, on progression of disease, receive CT7001 (samuraciclib) oral monotherapy in combination with fulvestrant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced solid tumours will receive CT7001(samuraciclib) oral monotherapy in a randomized, balanced, single-dose, two-treatment (fed v fasting), two-period, two-sequence crossover study followed by once daily continuous dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced solid malignancies will receive CT7001 (samuraciclib) and a new enteric capsule CT7001 (EC) (samuraciclib) oral monotherapy in a randomized, single blind, balanced, two treatment two period, two sequence crossover with one wash out period in between, followed by once daily continuous dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT7001</intervention_name>
    <description>Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression</description>
    <arm_group_label>Module 1 Part A</arm_group_label>
    <arm_group_label>Module 1 Part B</arm_group_label>
    <arm_group_label>Module 1 Part B-1 TNBC Expansion</arm_group_label>
    <arm_group_label>Module 4</arm_group_label>
    <other_name>Samuraciclib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT7001 in combination with fulvestrant</intervention_name>
    <description>Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression in combination with fulvestrant given as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter</description>
    <arm_group_label>Module 2 Part A</arm_group_label>
    <arm_group_label>Module 2 Part B</arm_group_label>
    <arm_group_label>Module 2 Part C</arm_group_label>
    <other_name>Samuraciclib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT7001 (in original vs enteric capsule)</intervention_name>
    <description>Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression</description>
    <arm_group_label>Module 6</arm_group_label>
    <other_name>Samuraciclib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Core Inclusion Criteria:&#xD;
&#xD;
          1. ECOG performance status 0 or 1 with no deterioration over the previous 2 weeks&#xD;
&#xD;
          2. Estimated life expectancy of greater than 12 weeks&#xD;
&#xD;
          3. Ability to swallow and retain oral medication&#xD;
&#xD;
          4. Women either of non-childbearing potential or of childbearing potential willing to&#xD;
             practice effective contraception for the duration of the study and for 6 months&#xD;
             (Module 1, Module 4) and 24 months (Module 2) after the last dose of CT7001&#xD;
&#xD;
          5. Sexually active male patients must be willing to use condoms with all sexual partners&#xD;
             for the duration of the study and for 3 months after the last dose of CT7001.&#xD;
&#xD;
          6. Provision of signed and dated, written informed consent&#xD;
&#xD;
        Core Exclusion Criteria:&#xD;
&#xD;
          1. Any other malignancy that has been active or treated within the past 3 years, with the&#xD;
             exception of cervical intraepithelial neoplasia and non-melanoma skin cancer&#xD;
&#xD;
          2. Any unresolved toxicity (except alopecia) from prior therapy of ≥ CTCAE Grade 2&#xD;
&#xD;
          3. Spinal cord compression or brain metastases, unless asymptomatic, stable, and not&#xD;
             requiring steroids for at least 4 weeks before the first dose of investigational&#xD;
             product (IP)&#xD;
&#xD;
          4. Refractory nausea and vomiting, chronic gastrointestinal (GI) disease or previous&#xD;
             significant bowel resection, with clinically significant sequelae that would preclude&#xD;
             adequate absorption of CT7001&#xD;
&#xD;
          5. Uncontrolled seizures&#xD;
&#xD;
          6. Active infection requiring systemic antibiotic, antifungal, or antiviral medication&#xD;
&#xD;
          7. Severe or uncontrolled medical condition or psychiatric condition&#xD;
&#xD;
          8. Active bleeding diatheses&#xD;
&#xD;
          9. Renal transplant&#xD;
&#xD;
         10. Known hepatitis B, hepatitis C, or human immunodeficiency virus infection&#xD;
&#xD;
         11. Breastfeeding or pregnancy&#xD;
&#xD;
         12. Receipt of systemic cytotoxic treatment for the malignancy within 28 days or ≤ 5&#xD;
             half-lives, whichever is shorter before the first dose of IP&#xD;
&#xD;
         13. Receipt of non-cytotoxic treatment for the malignancy within 5 half-lives of the drug&#xD;
             before the first dose of IP&#xD;
&#xD;
         14. Receipt of corticosteroids (at a dose &gt; 10 mg prednisone/day or equivalent) within 14&#xD;
             days before the first dose of IP&#xD;
&#xD;
         15. Receipt of any small-molecule investigational medicinal product (IMP) within 28 days&#xD;
             or ≤ 5 half-lives, whichever is shorter before the first dose of IP&#xD;
&#xD;
         16. Receipt of any biological IMP (e.g., immune checkpoint blockers, antibodies,&#xD;
             nanoparticles) within 42 days before the first dose of IP&#xD;
&#xD;
         17. Receipt of St John's Wort within 21 days before the first dose of IP or of another&#xD;
             concomitant medication, herbal supplement, or food that is a strong inhibitor or&#xD;
             inducer of CYP3A4, CYP2C19, CYP2D6, or P-glycoprotein (PGP) activity within 14 days&#xD;
             before the first dose of CT7001&#xD;
&#xD;
         18. Receipt of a blood transfusion (blood or blood products) within 14 days before the&#xD;
             first dose of IP&#xD;
&#xD;
         19. Known hypersensitivity to CT7001 or any excipient of the product&#xD;
&#xD;
         20. Impaired hepatic or renal function as demonstrated by any of the following laboratory&#xD;
             values:&#xD;
&#xD;
               1. Albumin &lt; 30 g/L&#xD;
&#xD;
               2. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 2.5 × the&#xD;
                  upper limit of normal (ULN)&#xD;
&#xD;
               3. &gt; 5.0 × ULN for patients with liver metastases&#xD;
&#xD;
               4. Total bilirubin &gt; 1.5 × ULN&#xD;
&#xD;
               5. Serum creatinine &gt; 1.5 × ULN&#xD;
&#xD;
         21. Liver function deteriorating in a manner that would likely make the participant meet&#xD;
             the AST, ALT, or bilirubin levels specified above at the time of the first dose of IP&#xD;
&#xD;
         22. Other evidence of impaired hepatic synthesis function&#xD;
&#xD;
         23. Inadequate bone marrow reserve or organ function as demonstrated by any of the&#xD;
             following laboratory values:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) &lt; 1.5 × 10^9/L&#xD;
&#xD;
               2. Platelet count &lt; 100 × 10^9/L&#xD;
&#xD;
               3. Haemoglobin &lt; 90 g/L&#xD;
&#xD;
         24. Persistent (&gt; 4 weeks) severe pancytopenia due to previous therapy rather than to&#xD;
             disease (ANC &lt; 0.5 × 10^9/L or platelets &lt; 50 x 10^9/L)&#xD;
&#xD;
         25. Cardiac dysfunction (defined as myocardial infarction within 6 months of study entry,&#xD;
             New York Heart Association Class II/III/IV heart failure, unstable angina, unstable&#xD;
             cardiac arrhythmias, or left ventricular ejection fraction &lt; 55 percent)&#xD;
&#xD;
         26. Mean resting QT interval corrected for heart rate by the Fridericia formula (QTcF) &gt;&#xD;
             470 msec obtained from 3 electrocardiograms (ECGs) obtained within 5 minutes of each&#xD;
             other prior to the first dose&#xD;
&#xD;
         27. Any clinically important abnormalities in rhythm, conduction, or morphology on resting&#xD;
             ECG (e.g., complete left bundle branch block, third degree heart block). Controlled&#xD;
             atrial fibrillation (AF) is permitted&#xD;
&#xD;
         28. Any factor that increases the risk of QTc prolongation or of arrhythmic events (e.g.,&#xD;
             heart failure, hypokalaemia, congenital long QT syndrome, immediate family history of&#xD;
             long QT syndrome or unexplained sudden death under 40 years of age)&#xD;
&#xD;
         29. In the opinion of the Investigator, unlikely to comply with study procedures,&#xD;
             restrictions, or requirements&#xD;
&#xD;
         30. A history of haemolytic anaemia or marrow aplasia&#xD;
&#xD;
         31. Has received a live-virus vaccination within 28 days or less of planned treatment&#xD;
             start&#xD;
&#xD;
        Additional Module 1A Inclusion Criteria:&#xD;
&#xD;
          1. Histological, radiological or cytological confirmation of an advanced&#xD;
             non-haematological malignancy not considered to be appropriate for further standard&#xD;
             treatment&#xD;
&#xD;
          2. Module 1A biopsy cohort only : at least one tumour suitable for repeat biopsy&#xD;
&#xD;
        Additional Module 1A Exclusion Criteria:&#xD;
&#xD;
        1. International normalised ratio (INR) ≥1.5&#xD;
&#xD;
        Additional Module 1B Inclusion Criteria&#xD;
&#xD;
          1. Histological or cytological confirmation of metastasis or locally advanced tumour&#xD;
&#xD;
          2. At least one line of systemic anti-cancer therapy&#xD;
&#xD;
          3. Disease measurable by RECIST v1.1&#xD;
&#xD;
        Additional Module 1B-1 (TNBC Expansion) Inclusion Criteria:&#xD;
&#xD;
          1. Histologically-confirmed carcinoma of breast not expressing oestrogen receptor (ER) or&#xD;
             progesterone receptor (PR) and negative for human epidermal growth factor receptor 2&#xD;
             (HER2)&#xD;
&#xD;
          2. Documented disease progression on or within 6 months of most recent cytotoxic prior&#xD;
             cytotoxic chemotherapy&#xD;
&#xD;
          3. Disease measurable by RECIST v1.1&#xD;
&#xD;
          4. Must have received at least one cytotoxic chemotherapy for metastatic/locally advanced&#xD;
             disease&#xD;
&#xD;
        Additional Module 1B-1 (TNBC Expansion) Exclusion Criteria:&#xD;
&#xD;
          1. No more than three lines of cytotoxic chemotherapy for metastatic/locally advanced&#xD;
             disease&#xD;
&#xD;
          2. No advanced, symptomatic visceral metastases&#xD;
&#xD;
          3. No known symptomatic central nervous system (CNS) metastases, carcinomatous meningitis&#xD;
             or leptomeningeal disease&#xD;
&#xD;
          4. Prior exposure to CT7001&#xD;
&#xD;
          5. Patients who are investigational site staff members directly involved in the conduct&#xD;
             of the trial and their family members, site staff members otherwise supervised by the&#xD;
             Investigator, or patients who are Carrick employees directly involved in the conduct&#xD;
             of the trial&#xD;
&#xD;
        Additional Module 2 Inclusion Criteria:&#xD;
&#xD;
          1. Women only&#xD;
&#xD;
          2. Pre- or peri-menopausal women must have initiated LHRHa at least 28 days prior to&#xD;
             first dose of CT7001/placebo&#xD;
&#xD;
          3. Histologically-confirmed, metastatic or locally advanced, ER+ve and/or PGR+ve and&#xD;
             HER2-ve breast cancer&#xD;
&#xD;
          4. Part A only: Disease measurable by RECIST v1.1&#xD;
&#xD;
          5. Documented objective disease progression while on, or within 6 months after the end&#xD;
             of, the most recent therapy&#xD;
&#xD;
          6. Must have received an aromatase inhibitor together with a CDK4/6 inhibitor in the same&#xD;
             line of therapy for locally advanced or metastatic disease or for treatment of early&#xD;
             breast cancer if the disease-free interval was &lt;12 months.&#xD;
&#xD;
          7. For Part B only: patients must have received at least 6 months clinical benefit with&#xD;
             the CDK4/6 as a line of therapy immediately preceding study entry. Patients who&#xD;
             received CDK4/6 inhibitor &lt; 6 months due to tolerability issues when at least 6 months&#xD;
             aromatase inhibitor was received.&#xD;
&#xD;
          8. Ability to receive intramuscular injections.&#xD;
&#xD;
        Additional Module 2 Exclusion Criteria:&#xD;
&#xD;
          1. Prior therapy with fulvestrant&#xD;
&#xD;
          2. More than 2 lines of endocrine treatment for locally advanced or metastatic disease&#xD;
&#xD;
          3. Part A Only: Prior treatment with more than one line of cytotoxic chemotherapy for&#xD;
             locally advanced or metastatic breast cancer.&#xD;
&#xD;
          4. Part B Only: Prior treatment with cytotoxic chemotherapy for locally advanced or&#xD;
             metastatic breast cancer or treatment with a mammalian target of rapamycin (mTOR)&#xD;
             inhibitor including, but not limited to, everolimus.&#xD;
&#xD;
          5. Patients with liver metastasis will be limited to approximately 30-40% of the enrolled&#xD;
             patients. l&#xD;
&#xD;
          6. Known hypersensitivity to CT7001, fulvestrant or any excipient of the investigational&#xD;
             products&#xD;
&#xD;
          7. Patients who are investigational site staff members directly involved in the conduct&#xD;
             of the trial and their family members, site staff members otherwise supervised by the&#xD;
             Investigator, or patients who are Carrick employees directly involved in the conduct&#xD;
             of the trial&#xD;
&#xD;
        Additional Module 4 Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be able to eat a high-fat meal, as provided by the study site, within a&#xD;
             30-minute period&#xD;
&#xD;
          2. Histological, radiological or cytological confirmation of an advanced&#xD;
             non-haematological malignancy not considered to be appropriate for further standard&#xD;
             treatment&#xD;
&#xD;
        Additional Module 4 Exclusion Criteria:&#xD;
&#xD;
        1. Patients who were unable to fast for at least 10 hours&#xD;
&#xD;
        Additional Module 6 Inclusion Criteria:&#xD;
&#xD;
        1. Histological, radiological or cytological confirmation of an advanced non-&#xD;
        haematological malignancy not considered to be appropriate for further standard treatment.&#xD;
&#xD;
        Additional Module 6 Exclusion Criteria:&#xD;
&#xD;
          1. Any concurrent gastrointestinal conditions, not covered in Core Protocol Exclusion&#xD;
             Criteria #4&#xD;
&#xD;
          2. Patients whom has received an agent that increases gastric pH (i.e. proton pump&#xD;
             inhibitors (PPI), H2 antagonists) within 2 days or 5 half-lives, whichever is shorter,&#xD;
             prior to PK Period Day 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Krebs, MBChB PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christie Hospital, Manchester, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site 42</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 54</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 31</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 37</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 49</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 38</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 34</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 55</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 47</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 39</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 36</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 43</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 44</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 46</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 51</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 50</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 48</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 41</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 33</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site 11</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site 5</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 12</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 13</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10</name>
      <address>
        <city>Liverpool</city>
        <zip>L69 3BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 9</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 8</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 4</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 2</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 6</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

